Medicines labeled for the same conditions
Alternatives to bimekizumab
7 other medicines are given the same way (subcutaneous) and in the same FDA class as bimekizumab or labeled mainly for the same use (psoriasis); the others include 2 interleukin-23 antagonists, 2 interleukin-17a antagonists and 1 interleukin-36 receptor antagonist (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as bimekizumab?
Psoriasis lists all 38 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Bimekizumab | this medicine | none listed | $8,073.83 per mL 160 mg/mL autoinjector | No | No current entry |
| Adalimumab-ryvk | Psoriasis | none listed | $499.12 per unit 40 mg/0.4 mL autoinjector | Yes | A presentation being discontinued |
| Risankizumabinterleukin-23 antagonist | Psoriasis | none listed | $22,774.36 per mL 150 mg/mL pen | No | No current entry |
| Ixekizumabinterleukin-17a antagonist | Psoriasis | none listed | $7,370.72 per mL 80 mg/mL autoinjector | No | No current entry |
| Secukinumabinterleukin-17a antagonist | Psoriasis | none listed | $3,946.35 per mL 300 mg dose/2 pens (150 mg/pen) | No | No current entry |
| Spesolimabinterleukin-36 receptor antagonist | Psoriasis | none listed | n/a | No | No current entry |
| Brodalumabinterleukin-17 receptor a antagonist | Psoriasis | none listed | n/a | Yes | No current entry |
| Tildrakizumabinterleukin-23 antagonist | Psoriasis | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Bimekizumab: the full record
- label, generics, price, shortages, recalls